Meirluc, I am a long and agree with your prognosis for a very positive future for NWBO. My point was that Pfizer chose to go for a bird in hand rather than risk of purchasing great future potential without any current regulator approval.
Your case is all about the future: "Within the next 3-5 years ..." and "will be introduced ..." and "will also be reflected ..." and "is going to be the next major treatment ..." and "will likely improve."
Bottom line, I agree with your FUTURE expectations, but we are not discussing the future, just the fact that Pfizer chose to buy a bird ALREADY in hand, not withstanding the greater future potential for NWBO.